In its report released last Tuesday, a nonprofit drug pricing research group claims that seven drugs have prices that do not align with any newly discovered increase in clinical benefit, leading to over $1.2 billion in excess drug spending in 2019, alone.
The nonprofit called out seven drugmakers in its report on "unsupported price increases" Tuesday. Drugmakers criticized the organization's methodology in response.
This webinar will explore how a banking platform approach could be the resource for your company.
The report found that Aimmune's AR101 and DBV's Viaskin Peanut lacked sufficient evidence to demonstrate that their benefits outweighed short-term risks. Aimmune and an allergy advocacy group criticized the report.
The PBM will incorporate cost-per-QALY analyses from ICER, but the program also drew some criticism.